Mirea, Andreea-Manuela
Toonen, Erik J. M.
van den Munckhof, Inge
Munsterman, Isabelle D.
Tjwa, Eric T. T. L.
Jaeger, Martin
Oosting, Marije
Schraa, Kiki
Rutten, Joost H. W.
van der Graaf, Marinette
Riksen, Niels P.
de Graaf, Jacqueline
Netea, Mihai G.
Tack, Cees J.
Chavakis, Triantafyllos
Joosten, Leo A. B.
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung
Article History
Received: 6 February 2019
Accepted: 17 April 2019
First Online: 2 May 2019
Ethics approval and consent to participate
: Inclusion of volunteers and experiments were conducted according to the principles expressed in the Declaration of Helsinki. All volunteers gave written informed consent before any material was taken.The CVON study was approved by the Ethical Committee of Radboud University Medical Center Nijmegen (N146846.091.13, 2013/505).The study of the cohort of 41 patients biopsy-diagnosed with NAFLD was approved by the institutional review bord of Radboudumc (no. 2016–2823).The Parelsnoer study was approved by the ethics committee of the VU University Medical Center (NL27783.029.09, 2009/107) and of UMC St. Radboud Nijmegen (NL27783.029.09, 09/066).The 500 Functional Genomic Project study was approved by the Ethical Committee of Radboud University Medical Center Nijmegen (NL42561.091.12, 2012/550).
: Not applicable.
: Erik J.M. Toonen is an employee of Hycult Biotech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.